文献速递心脑血管急症

静脉溶栓后早期替罗非班输注治疗卒中

Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke.
PubMed 文献 · N Engl J Med · 2025-07-04
一句话结论急性缺血性非心源性卒中溶栓后60分钟内启动24小时替罗非班静脉输注,可提高90天极佳功能结局比例,但症状性颅内出血略增。

这项3期多中心双盲随机安慰剂对照试验在中国38个中心纳入发病4.5小时内、不适合取栓的急性缺血性非心源性卒中患者,溶栓后60分钟内给予24小时替罗非班或安慰剂静脉输注。90天改良Rankin量表0~1分比例替罗非班组65.9%高于安慰剂组54.9%(RR 1.20,95%CI 1.07~1.34,P=0.001)。症状性颅内出血替罗非班组1.7%、安慰剂组0%,90天死亡率两组分别为4.1%和3.8%。作者认为早期替罗非班提高了极佳功能结局的可能性,颅内出血发生率低但替罗非班组高于安慰剂组。

要点

  • 发病4.5小时内、不适合取栓的急性缺血性非心源性卒中患者,溶栓后60分钟内启动24小时替罗非班静脉输注。
  • 90天mRS 0~1分:替罗非班组65.9% vs 安慰剂组54.9%,RR 1.20(95%CI 1.07~1.34),P=0.001。
  • 症状性颅内出血36小时内:替罗非班组1.7% vs 安慰剂组0%。
  • 90天死亡:替罗非班组4.1% vs 安慰剂组3.8%。
  • 溶栓药物为阿替普酶(75%患者)和替奈普酶(25%患者)。

适用人群与场景

  • 中国38个中心纳入的发病4.5小时内、接受静脉溶栓、不适合取栓的急性缺血性非心源性卒中患者。

诊断标准与关键阈值

  • 极佳功能结局定义为90天改良Rankin量表评分0~1分。
  • 安全结局为36小时内症状性颅内出血和90天死亡。

处置流程与药物剂量

  • 静脉溶栓后60分钟内启动替罗非班或安慰剂24小时静脉输注。
  • 溶栓药物为阿替普酶(75%患者)或替奈普酶(25%患者)。

研究设计与关键结果

  • 3期多中心双盲随机安慰剂对照试验,38个中心,替罗非班组414例、安慰剂组418例。
  • 90天mRS 0~1分:替罗非班组65.9% vs 安慰剂组54.9%,RR 1.20(95%CI 1.07~1.34),P=0.001。
  • 36小时内症状性颅内出血:替罗非班组1.7% vs 安慰剂组0%。
  • 90天死亡:替罗非班组4.1% vs 安慰剂组3.8%。

证据类型、等级与局限

  • 证据类型:3期多中心双盲随机安慰剂对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在发病4.5小时内接受溶栓的急性缺血性非心源性卒中患者中,早期替罗非班提高了极佳功能结局的可能性。
  • 作者报告颅内出血发生率低,但替罗非班组高于安慰剂组。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Intravenous thrombolysis remains a standard treatment for acute ischemic stroke within 4.5 hours after onset. Vascular reocclusion may occur after intravenous thrombolysis and may be preventable with an antiplatelet agent within the first 24 hours after thrombolysis. Tirofiban, a platelet glycoprotein IIb-IIIa receptor antagonist, has reduced macrovascular reocclusion in experimental models.

METHODS: In this phase 3, multicenter, double-blind, randomized, placebo-controlled trial conducted at 38 centers in China, we assigned patients with acute ischemic noncardioembolic stroke who presented within 4.5 hours after stroke onset and who were not eligible for thrombectomy to receive a 24-hour intravenous infusion of tirofiban or placebo within 60 minutes after intravenous thrombolysis. The primary efficacy outcome was an excellent functional outcome, defined as a score of 0 to 1 on the modified Rankin scale, at 90 days. The safety outcomes were symptomatic intracranial hemorrhage within 36 hours and death at 90 days.

RESULTS: A total of 414 patients were assigned to receive tirofiban and 418 to receive placebo. Thrombolytic agents included alteplase (in 75% of the patients) and tenecteplase (in 25%). At 90 days, a score of 0 to 1 on the modified Rankin scale was reported in a higher percentage of patients in the tirofiban group than in the placebo group (65.9% vs. 54.9%; risk ratio, 1.20; 95% confidence interval, 1.07 to 1.34; P = 0.001). Symptomatic intracranial hemorrhage occurred in 1.7% of the patients in the tirofiban group and none in the placebo group. Mortality at 90 days was 4.1% in the tirofiban group and 3.8% in the placebo group.

CONCLUSIONS: In patients with acute ischemic noncardioembolic stroke who underwent thrombolysis within 4.5 hours after onset, early tirofiban increased the likelihood of an excellent functional outcome. The incidence of intracranial hemorrhage was low but higher with tirofiban than placebo. (Funded by the Fundamental Research Funds for Central Universities; ASSET-IT ClinicalTrials.gov number, NCT06134622.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Tao C, Liu T, Cui T, et al. Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke. N Engl J Med. 2025. PMID: 40616232. doi:10.1056/NEJMoa2503678

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。